| Abstract | OBJECTIVE: To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson's disease (PD). METHODS: Thirty patients with PD prospectively received pramipexole 0.25 mg three times daily for 2 months. Unified Parkinson Disease Rating Scale (UPDRS) assessments were conducted at baseline and 2 months after treatment initiation. Improvement by 20% or more in the total score on the UPDRS was considered to indicate responsiveness. The PCR-restriction fragment length polymorphism analysis was used to analyze the DRD2 Taq1A and DRD3 Ser9Gly genotype. RESULTS: The DRD2 Taq1A allele frequencies were A141.7 (A1) and 58.3% (A2), and the DRD3 Ser9Gly allele frequencies were 68.3 (Ser) and 31.7% (Gly). When the subjects were grouped by the DRD3 Ser9Gly polymorphism, the response rates for pramipexole treatment were significantly higher in the Ser/Ser group (60%) than in the group containing the Gly allele (13%). There was a significant association between the DRD3 Ser9Gly polymorphism and response rate to pramipexole in PD patients (P = 0.024). When the subjects were grouped by the DRD2 Taq1A polymorphism, there were no significant differences among the three Taq1A genotypes. CONCLUSIONS: DRD3 Ser9Gly polymorphisms are significantly associated with the therapeutic efficacy of pramipexole in Chinese patients with PD. A large-scale and multi-dose group study in patients with PD is necessary for evaluating the impact of the genetic polymorphisms of the dopamine receptor on the therapeutic effects of pramipexole. |
| Authors | Ying-Zi Liu, Bei-Sha Tang, Xin-Xiang Yan, Jie Liu, Dong-Sheng Ouyang, Li-Nuo Nie, Lan Fan, Zhi Li, Wei Ji, Dong-Li Hu, Dan Wang, Hong-Hao Zhou
(Affiliation: Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, 410078, China.)
|
| Journal | European journal of clinical pharmacology
(Eur J Clin Pharmacol)
Vol. 65
Issue 7
Pg. 679-83
(Jul 2009)
ISSN: 1432-1041 [Electronic] Germany |
| PMID | 19396436
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Benzothiazoles
- Dopamine Agonists
- Receptors, Dopamine D2
- Receptors, Dopamine D3
- pramipexol
- DNA
|
| Topics |
- Aged
- Alleles
- Asian Continental Ancestry Group
(statistics & numerical data)
- Benzothiazoles
(therapeutic use)
- DNA
(blood, genetics, isolation & purification)
- Dopamine Agonists
(therapeutic use)
- Drug Administration Schedule
- Female
- Gene Frequency
- Genetic Predisposition to Disease
- Genotype
- Humans
- Male
- Middle Aged
- Parkinson Disease
(drug therapy)
- Polymorphism, Genetic
- Receptors, Dopamine D2
(genetics)
- Receptors, Dopamine D3
(genetics)
- Treatment Outcome
|
